[시장보고서]세계의 급성 췌장염 시장 - 규모, 점유율, 동향 분석 보고서 : 약제 클래스별, 유통 채널별, 지역별 부문 예측(2025-2033년)

세계의 급성 췌장염 시장 - 규모, 점유율, 동향 분석 보고서 : 약제 클래스별, 유통 채널별, 지역별 부문 예측(2025-2033년)

Acute Pancreatitis Market Size, Share & Trends Analysis Report By Drug Class (Analgesics, Antibiotics, Enzyme Inhibitors), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1869738

리서치사 : Grand View Research

발행일 : 2025년 10월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,845,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,332,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,305,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

급성 췌장염 시장 요약

세계의 급성 췌장염 시장 규모는 2024년 33억 7,000만 달러로 추정되었으며, 2033년까지 56억 달러에 이를 것으로 예측됩니다.

2025년부터 2033년까지 연평균 복합 성장률(CAGR) 5.8%로 성장할 전망입니다. 이 시장은 주로 췌장의 건강에 대한 인식 증가, 생활 습관병 증가, 진단 및 치료법 발전에 의해 견인되고 있습니다.

저침습 수술의 보급 확대, 영상 진단 기술의 향상, 신규 효소 보충 요법 및 항염증 치료법 개발이 시장의 추가 확대를 지원하고 있습니다. 또한 지속적인 임상 연구와 건강 관리 인프라 강화는 급성 췌장염 치료의 성장 전망을 더욱 강화하고 있습니다.

세계 급성 췌장염 시장은 헬스케어 관행 진화, 생활양식 변화, 기술 진보에 견인되어 꾸준히 성장을 계속하고 있습니다. 담석증, 과도한 알코올 섭취, 비만, 대사성 질환과 같은 위험 인자 증가가 췌장의 심각한 염증성 질환인 급성 췌장염(AP)의 발병률 상승에 기여하고 있습니다. 미국 국립의학 도서관에 의하면, 세계적으로 급성 췌장염은 연간 인구 10만명당 약 30-40명이 앓고 있어 미국에서는 소화기계 질환에 의한 입원의 주요 원인이 되고 있습니다. 이러한 상황은 진보된 진단 도구와 치료 개입에 대한 수요를 촉진하고 있습니다. 내시경 초음파 검사(EUS), CT 스캔, MRI와 같은 최첨단 영상 진단 기술은 조기 진단과 치료 정밀도를 높이는 한편, 저침습 수술과 효소 보충 요법은 회복의 성과를 향상시켜 입원 기간을 단축하고 있습니다.

참가자 개요
기업의 시장 포지셔닝 분석
기업 분류
전략 매핑
기업 프로파일
- AbbVie Inc
- Amgen Inc.
- Baxter
- Bayer AG
- Boehringer Ingelheim International GmbH
- Lilly USA, LLC
- Fresenius SE & Co. KGaA
- Hikma Pharmaceuticals PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Sanofi

JHS

영문 목차

영문목차

Acute Pancreatitis Market Summary

The global acute pancreatitis market size was estimated at USD 3.37 billion in 2024 and is projected to reach USD 5.60 billion by 2033, growing at a CAGR of 5.8% from 2025 to 2033. The market is largely driven by rising awareness of pancreatic health, an increasing prevalence of lifestyle-related disorders, and advances in diagnostic and therapeutic approaches.

Growing adoption of minimally invasive procedures, improved imaging technologies, and the development of novel enzyme replacement and anti-inflammatory treatments are further supporting market expansion. In addition, ongoing clinical research and enhanced healthcare infrastructure continue to strengthen growth prospects for acute pancreatitis management.

The global market for acute pancreatitis is consistently growing, driven by evolving healthcare practices, lifestyle changes, and technological advancements. The increasing prevalence of risk factors such as gallstones, excessive alcohol intake, obesity, and metabolic disorders has contributed to a rising incidence of acute pancreatitis (AP), a serious inflammatory condition of the pancreas. Globally, AP affects approximately 30-40 individuals per 100,000 population annually, according to the National Library of Medicine, and is a major cause of gastrointestinal hospitalizations in the U.S. These dynamics are fueling demand for advanced diagnostic tools and therapeuticinterventions. Cutting-edge imaging technologies, including endoscopic ultrasound (EUS), CT scans, and MRI, enhance early diagnosis and treatment precision, while minimally invasive procedures and enzyme replacement therapies improve recovery outcomes and shorten hospital stays.

Global Acute Pancreatitis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global acute pancreatitis market report based on drug class, distribution channel, and region.

Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
Analgesics
Antibiotics
Enzyme Inhibitors
Others
Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- Italy
- UK
- Spain
- Sweden
- Norway
Asia Pacific
- China
- Japan
- India
- Australia
- Thailand
- South Korea
- RoAPAC
Latin America
- Argentina
- Brazil
Middle East & Africa
- Saudi Arabia
- South Africa
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Global Acute Pancreatitis Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis

Chapter 4. Global Acute Pancreatitis Market: Drug Class Estimates & Trend Analysis

4.1. Drug Class Market Share, 2024 & 2033
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
4.4. Analgesic
- 4.4.1. Analgesic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Antibiotics
- 4.5.1. Antibiotics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Enzyme Inhibitors
- 4.6.1. Enzyme Inhibitors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Others
- 4.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Global Acute Pancreatitis Market: Distribution Channel Business Analysis

5.1. Distribution Channel Market Share, 2024 & 2033
5.2. Distribution Channel Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
5.4. Hospital Pharmacies
- 5.4.1. Hospital Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Retail Pharmacies
- 5.5.1. Retail Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Online Pharmacies
- 5.6.1. Online Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Global Acute Pancreatitis Market: Regional Business Analysis

6.1. Regional Market Share Analysis, 2024 & 2033
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
6.4. North America
- 6.4.1. North America Acute Pancreatitis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 6.4.2. U.S.
  - 6.4.2.1 Key Country Dynamics
  - 6.4.2.2 Type Disease Prevalence
  - 6.4.2.3 Regulatory Framework
  - 6.4.2.4 Reimbursement Framework
  - 6.4.2.5 U.S. Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.3. Canada
  - 6.4.3.1 Key Country Dynamics
  - 6.4.3.2 Type Disease Prevalence
  - 6.4.3.3 Regulatory Framework
  - 6.4.3.4 Reimbursement Framework
  - 6.4.3.5 Canada Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.4. Mexico
  - 6.4.4.1 Key Country Dynamics
  - 6.4.4.2 Type Disease Prevalence
  - 6.4.4.3 Regulatory Framework
  - 6.4.4.4 Reimbursement Framework
  - 6.4.4.5 Mexico Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Europe
- 6.5.1. Europe Acute Pancreatitis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 6.5.2. Germany
  - 6.5.2.1. Key Country Dynamics
  - 6.5.2.2. Type Disease Prevalence
  - 6.5.2.3. Regulatory Framework
  - 6.5.2.4. Reimbursement Framework
  - 6.5.2.5. Germany Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.3. France
  - 6.5.3.1. Key Country Dynamics
  - 6.5.3.2. Type Disease Prevalence
  - 6.5.3.3. Regulatory Framework
  - 6.5.3.4. Reimbursement Framework
  - 6.5.3.5. France Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.4. Italy
  - 6.5.4.1. Key Country Dynamics
  - 6.5.4.2. Type Disease Prevalence
  - 6.5.4.3. Regulatory Framework
  - 6.5.4.4. Reimbursement Framework
  - 6.5.4.5. Italy Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.5. UK
  - 6.5.5.1. Key Country Dynamics
  - 6.5.5.2. Type Disease Prevalence
  - 6.5.5.3. Regulatory Framework
  - 6.5.5.4. Reimbursement Framework
  - 6.5.5.5. UK Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.6. Spain
  - 6.5.6.1. Key Country Dynamics
  - 6.5.6.2. Type Disease Prevalence
  - 6.5.6.3. Regulatory Framework
  - 6.5.6.4. Reimbursement Framework
  - 6.5.6.5. Spain Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.7. Norway
  - 6.5.7.1. Key Country Dynamics
  - 6.5.7.2. Type Disease Prevalence
  - 6.5.7.3. Regulatory Framework
  - 6.5.7.4. Reimbursement Framework
  - 6.5.7.5. Norway Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.8. Sweden
  - 6.5.8.1. Key Country Dynamics
  - 6.5.8.2. Type Disease Prevalence
  - 6.5.8.3. Regulatory Framework
  - 6.5.8.4. Reimbursement Framework
  - 6.5.8.5. Sweden Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Asia Pacific
- 6.6.1. Asia Pacific Acute Pancreatitis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 6.6.2. China
  - 6.6.2.1. Key Country Dynamics
  - 6.6.2.2. Type Disease Prevalence
  - 6.6.2.3. Regulatory Framework
  - 6.6.2.4. Reimbursement Framework
  - 6.6.2.5. China Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.3. Japan
  - 6.6.3.1. Key Country Dynamics
  - 6.6.3.2. Type Disease Prevalence
  - 6.6.3.3. Regulatory Framework
  - 6.6.3.4. Reimbursement Framework
  - 6.6.3.5. Japan Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.4. India
  - 6.6.4.1. Key Country Dynamics
  - 6.6.4.2. Type Disease Prevalence
  - 6.6.4.3. Regulatory Framework
  - 6.6.4.4. Reimbursement Framework
  - 6.6.4.5. India Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.5. Australia
  - 6.6.5.1. Key Country Dynamics
  - 6.6.5.2. Type Disease Prevalence
  - 6.6.5.3. Regulatory Framework
  - 6.6.5.4. Reimbursement Framework
  - 6.6.5.5. Australia Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.6. Thailand
  - 6.6.6.1. Key Country Dynamics
  - 6.6.6.2. Type Disease Prevalence
  - 6.6.6.3. Regulatory Framework
  - 6.6.6.4. Reimbursement Framework
  - 6.6.6.5. Thailand Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.7. South Korea
  - 6.6.7.1. Key Country Dynamics
  - 6.6.7.2. Type Disease Prevalence
  - 6.6.7.3. Regulatory Framework
  - 6.6.7.4. Reimbursement Framework
  - 6.6.7.5. South Korea Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.8. RoAPAC
  - 6.6.8.1. Key Country Dynamics
  - 6.6.8.2. Type Disease Prevalence
  - 6.6.8.3. Regulatory Framework
  - 6.6.8.4. Reimbursement Framework
  - 6.6.8.5. RoAPAC Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Latin America
- 6.7.1. Latin America Acute Pancreatitis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 6.7.2. Argentina
  - 6.7.2.1. Key Country Dynamics
  - 6.7.2.2. Type Disease Prevalence
  - 6.7.2.3. Regulatory Framework
  - 6.7.2.4. Reimbursement Framework
  - 6.7.2.5. Argentina Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7.3. Brazil
  - 6.7.3.1. Key Country Dynamics
  - 6.7.3.2. Type Disease Prevalence
  - 6.7.3.3. Regulatory Framework
  - 6.7.3.4. Reimbursement Framework
  - 6.7.3.5. Brazil Acute Pancreatitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Middle East & Africa
6.9. Middle East & Africa Acute Pancreatitis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
6.10. Saudi Arabia
6.11. South Africa
6.12. Kuwait

Chapter 7. Competitive Landscape

7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
- 7.5.1. AbbVie Inc
  - 7.5.1.1. Overview
  - 7.5.1.2. Financial Performance
  - 7.5.1.3. Product Benchmarking
  - 7.5.1.4. Strategic Initiatives
- 7.5.2. Amgen Inc.
  - 7.5.2.1. Overview
  - 7.5.2.2. Financial Performance
  - 7.5.2.3. Product Benchmarking
  - 7.5.2.4. Strategic Initiatives
- 7.5.3. Baxter
  - 7.5.3.1. Overview
  - 7.5.3.2. Financial Performance
  - 7.5.3.3. Product Benchmarking
  - 7.5.3.4. Strategic Initiatives
- 7.5.4. Bayer AG
  - 7.5.4.1. Overview
  - 7.5.4.2. Financial Performance
  - 7.5.4.3. Product Benchmarking
  - 7.5.4.4. Strategic Initiatives
- 7.5.5. Boehringer Ingelheim International GmbH
  - 7.5.5.1. Overview
  - 7.5.5.2. Financial Performance
  - 7.5.5.3. Product Benchmarking
  - 7.5.5.4. Strategic Initiatives
- 7.5.6. Lilly USA, LLC
  - 7.5.6.1. Overview
  - 7.5.6.2. Financial Performance
  - 7.5.6.3. Product Benchmarking
  - 7.5.6.4. Strategic Initiatives
- 7.5.7. Fresenius SE & Co. KGaA
  - 7.5.7.1. Overview
  - 7.5.7.2. Financial Performance
  - 7.5.7.3. Product Benchmarking
  - 7.5.7.4. Strategic Initiatives
- 7.5.8. Hikma Pharmaceuticals PLC
  - 7.5.8.1. Overview
  - 7.5.8.2. Financial Performance
  - 7.5.8.3. Product Benchmarking
  - 7.5.8.4. Strategic Initiatives
- 7.5.9. Johnson & Johnson
  - 7.5.9.1. Overview
  - 7.5.9.2. Financial Performance
  - 7.5.9.3. Product Benchmarking
  - 7.5.9.4. Strategic Initiatives
- 7.5.10. Merck & Co., Inc.
  - 7.5.10.1. Overview
  - 7.5.10.2. Financial Performance
  - 7.5.10.3. Product Benchmarking
  - 7.5.10.4. Strategic Initiatives
- 7.5.11. Novartis AG
  - 7.5.11.1. Overview
  - 7.5.11.2. Financial Performance
  - 7.5.11.3. Product Benchmarking
  - 7.5.11.4. Strategic Initiatives
- 7.5.12. Sanofi
  - 7.5.12.1. Overview
  - 7.5.12.2. Financial Performance
  - 7.5.12.3. Product Benchmarking
  - 7.5.12.4. Strategic Initiatives

한글목차

급성 췌장염 시장 요약

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 세계 급성 췌장염 시장의 변수, 동향, 범위

제4장 세계의 급성 췌장염 시장 : 약물 클래스별 추정 및 동향 분석

제5장 세계의 급성 췌장염 시장 : 유통 채널별 비즈니스 분석

제6장 세계의 급성 췌장염 시장 : 지역별 비즈니스 분석

제7장 경쟁 구도